Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch of the Grappler^® Knotless Anchor System and Bridgeline™ Tape, enhancing the Company’s position in the fast-growing foot and ankle specific soft tissue market in 2024 and beyond. Both the Grappler^® Knotless Anchor System and Bridgeline™ Tape are highly complementary to a broad range of Paragon 28’s existing hardware products with several applications spanning multiple foot and ankle indications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105897232/en/

Figure 1: Grappler® Knotless Anchor System and Bridgeline™ Tape (Photo: Business Wire)

The Grappler^® Suture Anchor System is a sterile packed kit that includes all instrumentation needed to complete each case in multiple configurations designed to reduce waste and interoperative complexity.

Surgeon designer, Mark Prissel, DPM commented, “The Grappler^® Suture Anchor System is a comprehensive soft tissue anchoring product line that includes implants designed by and for foot and ankle surgeons for acute and chronic repairs. The implant sizes, suture lengths, and instrument ergonomics are all ideally equipped for efficient utilization in common tendon and ligament procedures, while complementing the broader Paragon 28 product portfolio seamlessly.”

The Bridgeline™ Tape is a huge leap forward in soft tissue stabilization. The tape features a novel semi-resorbable material with the ability to transition from rigid at the early stages of healing to a more natural physiological state. This product’s ability to transition over time is truly unique and is believed to foster better healing characteristics and expected to result in improved patient outcomes.

“We continue to believe soft tissue will play an increasingly important role in improving foot and ankle patient outcomes, and we could not be more excited to bring two new solutions to market to start the year. Many of the procedures we aim to treat at Paragon 28 involve some element of soft tissue compromise and we expect both of these products to be complementary to a large portion of our portfolio,” commented Albert DaCosta, Paragon 28’s CEO. “I am especially proud of what we accomplished with the Bridgeline™ Tape. With that product, we set out with a desire to create an optimal environment for healing with less scarring and we believe this unique solution accomplishes that goal and, importantly, will result in optimal treatment for each patient.”

The Grappler^® Knotless Anchor System and Bridgeline™ Tape bolsters Paragon 28’s soft tissue offering which includes the Paratrooper™ Plantar Plate System, TenoTac™ 2.0 Soft Tissue Fixation System, Grappler^® Interference Screw System, and Grappler Soft Tissue Anchor System. With this comprehensive portfolio, Paragon 28^® provides its customers with a single source to address their foot and ankle soft tissue needs.

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28, Inc. is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28^® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Paragon 28’s business in general, see Paragon 28’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Disclaimer

Dr. Prissel may report consulting and royalty fees from Paragon 28 in connection with the provision of product development services to Paragon 28.

Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240105897232/en/